Evaluation of one year response of treatment naive chronic hepatitis B patients to 245 mg/day tenofovir disoproxil fumarate [Naif kronik hepatit B hastalarinin bir yillik 245 mg/gün tenofovir disoproksil fumarate tedavi sonuçlarinin de?erlendirilmesi]

Basit Öğe Kaydı
dc.contributor.authorDemir N.A.
dc.contributor.authorKölgelier S.
dc.contributor.authorDemir L.S.
dc.contributor.authorSümer S.
dc.contributor.authorDikici N.
dc.contributor.authorÖzçimen S.
dc.contributor.authorInkaya A.C.
dc.date.accessioned2020-03-26T18:44:39Z
dc.date.available2020-03-26T18:44:39Z
dc.date.issued2013
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractObjective: In this study treatment response of 201 chronic hepatitis B (CHB) patients to 245 mg/day tenofovir disoproxil fumarate (TDF) was evaluated upon 48th week of treatment. Material and Method: This retrospective study included 201 treatment naive chronic hepatitis B patients who admitted to infectious diseases clinics of Adiyaman State Hospital, Adiyaman 82nd Year State Hospital and Selçuk University Selçuklu Medical Faculty between 01-Jan-2010 and 31-Dec-2011. Indication for biopsy was defined using American Association for the Study of Liver Disease (AASLD) criteria. Patient charts were retrospectively reviewed. Data were entered to SPSS 16.0 package program. Regarding statistical evaluation chi square test was used for cathegorical variables, and T test, Mann Whitney U test was used for continous variables. For analysis of repeated measurements variance analysis for repeated measures was used and significant groups were tested by signed rank test. p<0.05 was considered statistically significant. Results: One hundred thirty eight (68.7%) patients were males, 63 (31.3%) were females, and mean age was 39.9±12.5. HBeAg was positive in 88 (43.8%) and anti-HBe was positive in 113 (56.2%) patients. Median value for HBV DNA was 52920000 (6032800-34x109) IU/mL, ALT was 98.0 (14.0-665.0) u/L. At 24th week HBV DNA level was below 400 copy/ml in 57% of HBeAg positive and 69.5% of HBeAg negative patients and at 48th week in 81.3% of HBeAg positive and 89% of HBeAg negative patients. At 24th week of treatment ALT level normalized in 64.4% of HBeAg positive and 67.3% of HBeAg negative patients and at 48th week in 83% of HBeAg positive and 79% of HBeAg negative patients. ALT, and HBV DNA values significantly decreased relative to controls. Follow up did not reveal any significant change in creatinine, phosphor, calcium and ALP values. Conclusion: We conclude that TDF treatment was effective and safe during follow up. Because long term treatment is needed for CHB, more long term studies with big sample sizes are needed to determine effectiveness and side effects of tenofovir treatment.en_US
dc.identifier.endpage62en_US
dc.identifier.issn1305-2381en_US
dc.identifier.issue2en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage57en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12395/30030
dc.identifier.volume9en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.relation.ispartofNobel Medicusen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectAdverse effectsen_US
dc.subjectChronic hepatitis Ben_US
dc.subjectEffectivenessen_US
dc.subjectTDFen_US
dc.titleEvaluation of one year response of treatment naive chronic hepatitis B patients to 245 mg/day tenofovir disoproxil fumarate [Naif kronik hepatit B hastalarinin bir yillik 245 mg/gün tenofovir disoproksil fumarate tedavi sonuçlarinin de?erlendirilmesi]en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu